syndecan-1在结直肠癌中的表达及意义

目的研究syndecan-1在结直肠癌中的表达，探讨它与肿瘤生长和预后的关系。方法采用免疫组织化学染色技术，检测syndecan-1在结直肠癌及其周围正常组织中的表达，初步分析它与结直肠癌临床病理特征和临床预后的关系。结果3l例肿瘤组织切片中，syndecan-1表达阳性者仅1例（3．2％），正常组织中syndecan-1表达阳性者29例（93．5％），syndecan-1表达阳性率在两组间的差异有统计学意义（P〈0．01）。syndecan-1主要表达在正常肠黏膜上皮，肿瘤间质中的表达呈弱阳性。结论syndecan-1主要表达在正常结直肠黏膜上皮，肿瘤细胞中极少表达。     

环氧合酶-2在预测结直肠癌肝转移中的价值

目的研究环氧合酶-2（COX-2）在结直肠癌组织中的表达,探讨其与结直肠癌肝转移的关系。方法免疫组化法检测无肝转移、术时合并肝转移和术后发生肝转移的各30例结直肠癌组织以及30例癌旁正常黏膜组织（对照组）中的COX-2表达水平,分析其与性别、年龄、Dukes分期等临床特征之间的联系,比较无肝转移、术时肝转移、术后肝转移的结直肠癌组织和癌旁正常黏膜组织中的COX-2表达水平。结果COX-2表达情况：在结直肠癌组织中的表达显著高于癌旁正常黏膜组织（P〈0．05）;在术时肝转移组和术后肝转移组中的表达均显著高于无肝转移组（P〈0．05）;在结直肠癌组织中的表达与性别、年龄、分化等级、病理类型、术前癌胚抗原（CEA）和糖链抗原19-9（CA19-9）无关,与Dukes分期、淋巴结转移有关。结论COX-2过度表达与结直肠癌发生、发展、肝转移相关,对结直肠癌肝转移早期诊断有一定的应用价值。     

乙肝病毒感染与结直肠癌肝转移

结直肠癌最常见的远处转移部位是肝脏，有报道临床确诊为结直肠癌时，已有２０％～４０％发生了肝转移［１］。一般认为结直肠癌较少转移到肝硬化的肝脏。我们统计本院１９９０年１月至１９９９年１２月收治的结直肠癌患者３３８例，发现肝硬化患者并不多，而乙型肝炎表而抗原（ＨｂｓＡｇ）阳性与阴性者相比，前者肝转移率较低。 １．临床资料：３３８例患者中，男２０３例，女１３５例，年龄２５～９１（平均６２）岁。，ＨＢｓＡｇ阳性者（即感染组）５０例，阴性者（即非感染组）２８８例，肝转移率，感染组８．０％（４／５０），非感…     

趋化因子受体CXCR4在结直肠癌组织中的表达及其与临床病理特征的关系

目的观察趋化因子受体CXCR4在结直肠癌组织中的表达及其临床意义,探讨基质衍生因子SDF-1（CXCL12）-CXCR4生物学轴在结直肠癌侵袭转移中的作用。方法免疫组织化学法检测53例结直肠癌组织及27例正常黏膜组织中CXCR4的表达及分布,并分析高表达CXCR4与结直肠癌患者临床病理特征的关系。反转录-聚合酶链反应（RT—PCR）、Western印迹方法检测27例结直肠癌肿瘤组织、正常黏膜及5例肝转移灶内CXCR4 mRNA表达及CXCR4蛋白表达水平。结果53例结直肠癌组织中CXCR4表达阳性率为73．6％,高表达率（表达超过50％细胞）为45．3％;有淋巴结转移组CXCR4高表达率（65．4％）明显高于无淋巴结转移组（25．9％）（P〈0．01）。并与肿瘤血管淋巴管浸润有关。随着临床分期的增加,肿瘤组织中CXCR4高表达率有升高趋势,但差异无统计学意义（P〉0．05）。CXCR4的表达与患者肿瘤部位、大小、浸润深度无关（P〉0．05）。27例新鲜结直肠癌组织中CXCR4mRNA及蛋白表达水平明显高于相应的正常黏膜组织（P〈0．01）;5例肝转移灶组织中CXCR4表达显著高于对应的原发灶（P〈0．01）。结论趋化因子受体CXCR4是一类参与结直肠癌病程进展的重要分子,CXCL12-CXCR4信号通路有望成为结直肠癌治疗的新靶点。     

脾酪氨酸激酶基因甲基化与结直肠癌临床病理特征之间的关系

目的探讨脾酪氨酸激酶（Syk）基因甲基化、表达水平与结直肠癌患者临床病理特征及预后之间的关系。方法收集2001年1～12月间经手术治疗的120例结直肠癌标本．采用甲基化特异性聚合酶链反应（MSP）和逆转录-聚合酶链反应（RT—PCR）分析Syk基因的甲基化状态和表达情况，并分析Syk基因甲基化失表达与结直肠癌临床病理特衙和生存预后之间的关系。结果（1）120例结直肠癌患者中，48例肿瘤组织未检测到Syk基因的表达，而正常组织Syk基凶均表达；差异有统计学意义（X^2=60，P=0．000）。（2）发生甲基化的37例肿瘤组织中，Syk基因均失去表达。未发生甲基化的83例中，仅11例失表达；而癌旁匹配的正常组织均有表达。（3）Syk基因的甲基化状态与结直肠癌的淋巴结转移状态、病理分期密切相关，而与其他临床参数无关。（4）术后随访资料表明，Syk基因甲基化组患者的3年生存率明显低于未甲基化组（73．5％比95．7％，P=0．007）；而术后复发转移率明显高于未甲基化组（32．4％比8．4％，P=0．02）。结论Syk基因过甲基化失表达参与了结直肠癌的发生，导致结直肠癌侵袭性增强，患者术后复发转移率升高，3年生存率降低。     

Nemo样激酶在结直肠癌组织中的表达及其临床意义

目的研究Nemo样激酶（NLK）基因在结直肠癌组织中的表达情况及其临床意义。方法选取2001年1月至2009年12月间在上海第二军医大学附属长海医院肛肠外科行手术治疗患者的肠黏膜组织,其中正常黏膜组56例（行吻合器痔上黏膜环切钉合术的混合痔患者）;结直肠腺瘤组51例：结直肠癌组712例;转移性结直肠癌组21例。将选取的肠黏膜组织标本制作成组织芯片,采用Envision免疫组织化学法检测NLK的表达情况,并分析NLK的表达水平与临床病理因素的关系。结果NLK的表达阳性率从正常黏膜（75．0％,42／56）、结直肠腺瘤（86．3％,44／51）到结直肠癌[Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为92．5％（49／53）、90．1％（281／312）、91．9％（274／298）和98．0％（48／49）1依次升高。NLK的表达水平与结直肠癌淋巴结转移（P=0．027）、肿瘤远处转移（P=0．000）、肿瘤TNM分期（P=0．000）和复发率（P〈0．01）呈正相关。NLK在低分化和黏液腺癌结直肠癌中的表达（77．5％,62／80）低于高一中分化（93．4％,590／632;P=0．019）;在直肠癌中的表达水平（96．8％,361／373）明显高于结肠癌（85．8％,291／339;P〈0．01）。单因素和多因素分析显示,NLK的表达与结直肠癌患者总体生存率和无瘤生存率呈负相关（P〈0．01）,是结直肠癌患者的独立预测因素。NLK阳性表达率在21例转移性结直肠癌的正常黏膜、转移癌组织和原发癌组织中的表达率分别为57．1％（12／21）、76．2％（16／21）和81．0％（17／21）,后两者比较,差异无统计学意义（P=0．851）;而前者与原发癌比较,差异有统计学意义（P=0．010）。结论NLK在结直肠癌中可能发挥促癌作用,且具有预后判断的价值。     

FAK和VEGF在直肠癌中的表达及其相互关系的研究

目的：检测粘着斑激酶（FAK）和血管内皮生长因子（VEGF）在直肠癌中的表达及其与侵袭和转移的关系，探讨二者的相关性。方法：采用免疫组织化学SABC法，观察86例直肠癌及30例非直肠癌组织中FAK和VEGF的表达情况。结果：FAKVEGF在直肠癌中的阳性率分别为80％和59％。在非直肠癌组织中的阳性表达率分别为10％和13％。FAKF和VEGF在侵及浆膜层直肠癌病例中的表达明显高于未侵五2浆膜层者，二者之间差异性有统计学意义（P〈0．05）；有淋巴结转移组与无淋巴结转移组比较差异有统计学意义（P〈0．05），FAK与VEGF阳性表达呈正相关（p〈0．01）。结论：FAK、VEGF在直肠癌的侵袭和转移中起重要作用，二者在直肠癌中表达升高可以作为预测直肠癌侵袭和转移的指标     

APCDD1在直肠癌及结直肠腺瘤中的定量表达

目的建立荧光定量逆转录-聚合酶链反应（RT—PCR）方法检测APCDD1 mRNA基因表达的方法，了解直肠癌及结直肠腺瘤组织中APCDD1 mRNA的表达水平。方法用荧光定量PCR方法检测86例直肠癌及癌旁组织、20例结直肠腺瘤及配对的正常黏膜组织APCDD1 mRNA相对表达水平并比较其差异。结果75％的结直肠腺瘤和65％的直肠癌表达上调，86例直肠癌APCDD1 mRNA平均相对表达水平为正常黏膜组的4．712倍，20例结直肠腺瘤中APCDD1 mRNA平均相对表达水平为正常黏膜组的3．872倍，直肠癌组和结直肠腺瘤组均较正常黏膜组织上调，差异有统计学意义（P〈0．05）。结论APCDD1 mRNA表达在腺瘤和直肠癌中表达上调，但在直肠癌中与病理分级无明显相关。     

结直肠癌中抑癌基因ING1的表达研究

目的 探讨抑癌基因ING1及其蛋白p33／ING1在结直肠癌中的表达。方法 用RT-PCR检测35例散发性结直肠癌中ING1 mRNA的表达水平，并应用S-P法检测60例散发性结直肠癌及正常黏膜组织中p33／ING1蛋白的表达。结果 结直肠癌组织、正常黏膜组织中p33／ING1蛋白阳性表达率分别为43．3％（26／60）、100％（60／60），两者比较差异有统计学意义（P＜0．01）。p33／ING1在无淋巴结转移组及淋巴结转移组中的阳性表达率分别为57．6％（19／33）、25．9％（7／27），两者比较差异有统计学意义（P〈0．05）。在Dukes A、B期和Dukes C、D期患者癌组织中p33／ING1的阳性表达率分别为56．7％（17／30）、30．0％（9／30），两者比较差异有统计学意义（P＜0．05）。结论 ING1及p33／ING1蛋白的低表达与散发性结直肠癌发生、发展密切相关，临床分期越差者表达水平越低。     

结直肠癌组织5-脂氧合酶的表达与患者临床病理因素的关系

目的 探讨结直肠癌组织中5-脂氧合酶（5-LOX）的表达与患者临床病理因素的关系.方法 采用免疫组化SP法检测52例结直肠癌患者肿瘤组织中5-LOX的表达,分析5-LOX与结直肠癌患者临床病理因素的关系.结果 52例结直肠癌标本中,5-LOX表达阳性者38例（73.1％）.5-LOX阳性表达率淋巴结转移组[87.8％（36/41）]高于无转移组 [18.2％（2/11）,P＜0.05],浸润较深组[T3～T4,81.1％（30/37）]高于浸润较浅组[T1～T2,53.3％（8 /15）,P＜0.05];Ⅲ、Ⅳ期组[79.5％（31/39）]高于Ⅰ、Ⅱ期组[53.8％（7/13）,P＜0.05];低分化和未分化组 [100％（24/24）]高于高、中分化组[50.0％（14/28）,P＜0.05];而肿瘤大小、脉管侵犯、腹膜转移与5-LOX阳性表达率无关. 结论 5-LOX在结直肠癌组织中的阳性表达与肿瘤淋巴转移、浸润深度、分化程度和TNM分期有关.     

Association of angiogenesis markers with lymph node metastasis in early colorectal cancer

HYPOTHESIS: We hypothesized that p53 mutations (mp53) are associated with decreased expression of thrombospondin 1 (TSP-1) and that decreased TSP-1 expression is associated with lymph node metastases. DESIGN: A retrospective study of lymphatic mapping and pathologic determination of angiogenesis markers in primary colorectal cancer. SETTING: Tertiary care cancer institute. PATIENTS: Sixty-one patients with colorectal cancer underwent lymphatic mapping. Lymph nodes that stained negative by hematoxylin-eosin were examined with immunohistochemistry for micrometastases. Primary tumors were analyzed by immunohistochemistry for mp53 and TSP-1 expression. The t test and the Mann-Whitney U test were used to examine the mean difference in TSP-1 expression between tumors. MAIN OUTCOME MEASURES: Mutant p53 expression, TSP-1 expression, and metastatic progression. RESULTS: Thirty-six of the 61 patients (59%) had nodal metastases shown by hematoxylin-eosin or immunohistochemistry in the sentinel node (N2, N1, N1mi, or N0[i+]). Patients with a truly negative sentinel node (pN0[i-][sn]) had significantly higher TSP-1 expression compared with those with some degree of nodal metastases (57.7 vs 30.1; P < .001). Acquisition of mp53 was associated with a decreased mean TSP-1 expression. Tumors without mp53 expression had a mean TSP-1 optical density value of 51.3 while tumors with elevated mp53 had a mean TSP-1 optical density value of 31.8 (P < .03). CONCLUSIONS: Patients with primary colorectal cancer with low TSP-1 expression, with or without detection of mp53 gene product, are more likely to harbor lymph node metastasis than patients with higher expression. Patients with a truly negative sentinel node (pN0[i-][sn]) frequently have higher expression of TSP-1 that may have inhibited metastatic progression. Further studies will investigate the relationship between mp53, TSP expression, and disease progression.     

The expression of thrombospondin-1 in benign prostatic hyperplasia and prostatic intraepithelial neoplasia is decreased in prostate cancer

OBJECTIVE: To evaluate the immunohistochemical expression of thrombospondin (TSP), a potent inhibitor of angiogenesis, in human benign prostatic hyperplasia (BPH) and prostate cancer. MATERIALS AND METHODS: The expression of TSP-1, TSP-2 and CD36 receptor was assessed in 73 tissue specimens using immunohistochemistry; specimens were from 32 patients with BPH, seven with prostatic intraepithelial neoplasia (PIN) and 34 with cancer. RESULTS: Immunohistochemistry showed that all 39 patients with BPH and PIN had TSP-1-positive glands. In contrast, none of the 34 patients with cancer had positive TSP-1 staining in the cancer tissue. All 73 patients were positive for TSP receptor CD36 and negative for TSP-2. CONCLUSIONS: TSP is expressed in BPH, down-regulated in PIN and absent in prostate cancer tissue. This may indicate that TSP is important in prostate cancer progression. Further studies are needed to understand the significance of these findings for the malignant transformation of the prostate gland.     

Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia

OBJECTIVE: To evaluate the expression of thrombospondin-1 (TSP-1, a potent inhibitor of angiogenesis) and vascular endothelial growth factor (VEGF, an important angiogenic factor in solid tumours) in prostate cancer, and their relationship with p53 status. PATIENTS AND METHODS: Using immunohistochemistry, the expression of VEGF, TSP-1 and p53 was assessed in 82 archival tissue specimens from 23 patients with benign prostatic hyperplasia (BPH), 22 with localized prostate cancer and 37 with metastatic prostate cancer. Seven of the last group had received androgen deprivation therapy. The relationship between the expression of VEGF, TSP-1 and p53 status was also evaluated with tumour grade and stage in patients with prostate cancer. RESULTS: The seven patients receiving hormonal treatment were excluded from the analysis because androgen deprivation significantly increased TSP-1 and decreased VEGF expression (both P < 0.01). Immunohistochemical analysis showed significantly higher VEGF and significantly lower TSP-1 expression (both P < 0.01) in prostate cancer than in BPH tissues. There was also significantly higher VEGF and significantly lower TSP-1 expression (both P < 0.05) in tissues from metastatic than localized prostate cancer. There was no significant correlation between VEGF or TSP-1 expression and Gleason score, but a significant inverse correlation between TSP-1 and VEGF expression. There was a significant association between VEGF expression and p53 status (P < 0.05), but TSP-1 expression was not associated with p53 status. CONCLUSIONS: Angiogenic factors, including VEGF and TSP-1, might be important in the development and progression of prostate cancer. These changes seem to be influenced by p53 status. Identifying the angiogenic factors involved in prostate cancer might lead to the development of diagnostic or therapeutic strategies based on anti-angiogenesis.     

Up-regulation of matrix metalloproteinase 9 by thrombospondin 1 in gastric cancer

BACKGROUND: Matrix metalloproteinase 9 (MMP-9) plays a key role in tumor cell invasion. It was recently reported that plasma levels of MMP-9 in patients with gastric cancer correlate with the tumors' metastatic potential. We previously demonstrated that thrombospondin 1 (TSP-1) up-regulates MMP-9 expression by endothelial cells and promotes tumor cell invasion. We hypothesized that TSP-1 plays a role in the up-regulation of MMP-9 in gastric cancer. METHODS: MMP-9, TSP-1, and CSVTCG-specific TSP-1 receptor expression were measured by immunohistochemical staining in 31 consecutive gastric adenocarcinomas from patients who did not undergo neoadjuvant chemotherapy or radiation therapy. Additionally, we measured TSP-1, CSVTCG-specific TSP-1 receptor, and MMP-9 expression by Western blotting, zymography, and immunohistochemical staining in AGS gastric adenocarcinoma cells. We also investigated the effect of TSP-1 on MMP-9 expression by AGS cells. RESULTS: TSP-1 localized to the tumor-associated extracellular matrix. CSVTCG-specific TSP-1 receptor and MMP-9 colocalized to tumor cells, fibroblasts, and tumor-associated microvessels. Intense staining for TSP-1, CSVTCG-specific TSP-1 receptor, and MMP-9 correlated with markers of aggressive tumor behavior. AGS gastric adenocarcinoma cells expressed high levels of CSVTCG-specific TSP-1 receptor but not TSP-1. TSP-1 up-regulated MMP-9 expression by AGS cells. CONCLUSIONS: We conclude that TSP-1 plays a role in the up-regulation of MMP-9 expression in gastric cancer. Our data also suggest a correlation between expression of TSP-1, CSVTCG-specific TSP-1 receptor, and MMP-9 and the acquisition of an aggressive tumor phenotype.     

血小板反应素-1在胃癌及转移淋巴结中的表达及其与血管生成相关性的研究

目的检测血小板反应素-1（TSP-1）在原发性胃癌及转移淋巴结组织中的表达情况,并分析其与胃癌临床病理学参数及血管生成的关系。方法应用免疫组织化学方法检测72例成对胃癌组织、癌旁正常组织（距离癌灶≥5cm）及胃周淋巴结组织中TSP-1及血管内皮生长因子（VEGF）的表达和微血管密度（MVD）的变化。采用半定量评分系统评估染色结果,并分析TSP-1蛋白表达与VEGF、MVD及胃癌临床病理学参数的关系。结果①TSP-1蛋白在胃癌组织中表达阳性率为45．8％（33／72）,在癌旁正常组织中为90．3％（65／72）,在转移淋巴结组织中为50．8％（30／59）,其在胃癌组织和转移淋巴结组织中的蛋白表达阳性率明显低于其在癌旁正常组织中的表达阳性率呼=32．710,P=0．000;）f=25．298,P=0．000）,其在胃癌组织中的蛋白表达阳性率与其在转移淋巴结组织中的表达阳性率比较,差异无统计学意义贸X=0．327,P=0．568）。②胃癌组织中TSP-1蛋白表达阳性率与淋巴结转移有关,即在有淋巴结转移的胃癌组织中TSP．1蛋白表达阳性率明显低于其在无胃周淋巴结转移组织中的表达阳性率（Z=-2．573,P=0．010）。③TSP-1在胃癌组织及转移淋巴结组织中的蛋白表达与VEGF表达（rs=-0．309,P=0．008;rs=-0．269,P=0．040）及MVD（rs=-0．348,P=0．003;rs=-0．272,P=0．037）呈负相关。结论TSP-1在胃癌组织及转移淋巴结组织中的蛋白表达均降低且与VEGF表达和MVD呈负相关,提示TSP-1可能是一个肿瘤血管生成抑制因子。     

血小板反应素-1在前列腺癌患者中的表达及意义

摘要：目的探讨血小板反应素1（TsP一1）在前列腺癌患者癌组织及其外周血中的表达及其意义。方法应用免疫组化技术检测TSP-1在前列腺癌组织（前列腺癌组）中的表达;以半定量RTPCR技术检测TSP-lmRNA在患者外周血中的表达,并与前列腺增生患者（前列腺增生组）进行比较。结果前列腺癌组TSP-1阴性表达6例,弱阳性表达16例,阳性表达4例,增生组TSP-1弱阳性表达12例,阳性表达16例,无阴性表达,前列腺癌组TSP-1表达强度较增生组显著降低（P〈O．01）;TSP-1mRNA在前列腺癌组织中较前列腺增生组织中表达明显下调（P〈0．01）。TSPlmRNA在前列腺癌组外周血中的表达较增生组明显下调（P〈o．01）。结论TSP-1基因及蛋白表达水平在前列腺癌组织中明显下调,在前列腺癌患者外周血中表达水平明显下调。     

Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer

OBJECTIVES: Superficial bladder cancer (SBC) presents a difficult clinical dilemma at diagnosis as only a small subgroup of patients will subsequently develop invasive disease. Study of cancer biology has found that angiogenesis is central to growth and spread. This study examines the relationship between the angiogenic inhibitory factor Thrombospondin-1 (TSP-1) at initial presentation and subsequent progression of SBC. METHODS: Using immunohistochemistry, 220 cases of SBC were examined for pattern and extent of expression of TSP-1 at initial presentation. RESULTS: TSP-1 was detected in perivascular tissue, at the epithelial-stromal junction, in the stroma and in tumour cells and reduced perivascular TSP-1 staining at presentation was an independent predictive factor for the subsequent development of muscle invasive or metastatic disease. CONCLUSION: This adds further weight to the theory that TSP-1 plays a major part in the biology of bladder cancer possibly through the control of angiogenesis.     

黑色素瘤缺乏因子2和赖氨酰氧化酶在结直肠癌组织中的表达及与预后的关系

目的:探讨结直肠癌组织中黑色素瘤缺乏因子2(AIM2)和赖氨酰氧化酶(LOX)表达与临床病理参数及预后的关系。方法:对2010年10月—2014年2月收治的98例结直肠癌患者进行研究,检测结直肠癌组织及癌旁组织中AIM2和LOX的表达,分析AIM2和LOX表达与临床病理参数的相关性,Kaplan-Meier生存曲线分析不同AIM2、LOX表达患者总生存率的差异,Cox比例风险回归模型分析结直肠癌患者预后的影响因素。结果:与癌旁组织相比,结直肠癌组织中AIM2表达下调,而LOX表达上调(P<0.05)。AIM2表达与TNM分期和肿瘤分化程度相关(P<0.05),而LOX表达与肿瘤浸润深度、TNM分期和淋巴结转移相关(P<0.05)。AIM2阳性患者的生存率明显高于AIM2阴性患者(P<0.05),而LOX阳性患者的生存率明显低于LOX阴性患者(P<0.05)。Cox比例风险回归分析结果显示,TNM分期、AIM2和LOX表达是结直肠癌患者预后的独立影响因素(P<0.05)。结论:结直肠癌组织中AIM2表达下调而LOX表达上调,并与结直肠癌的进展和患者的预后有关,检测AIM2、LOX有助于患者的预后评估。     

前列腺癌TSP-1的表达与血管新生的关系及意义

目的：探讨良性前列腺增生及前列腺癌中血管生成与血小板反应素-1（TSP-1）表达的相关性。方法：应用免疫组织化学方法检测32例良性前列腺增生和32例前列腺癌组织中TSP-1的表达及微血管密度（MVD）。结果：前列腺癌组织中TSP-1表达显著低于良性前列腺增生（P〈0．05）,MVD则明显升高（P〈0．05）;随着肿瘤分期的进展,浸润转移性癌中TSP-1的表达降低甚至缺失,而MVD却逐渐升高。结论：TSP-1在前列腺癌中呈低表达,与前列腺癌的血管新生相关;作为一种内源性血管新生抑制剂,它具有抑制肿瘤生长及血管新生的作用。     

抑癌候选基因Ndrg2在结直肠癌组织中的表达特点及意义

目的 探讨抑癌候选基因Ndrg2在不同分化级别结直肠癌组织中的表达特点,分析其调控结直肠癌细胞分化的意义.方法 收集50例不同分化级别结直肠癌组织标本,分别通过免疫组织化学染色及蛋白印迹分析检测Ndrg2的表达;以150点结直肠癌组织芯片大样本分析Ndrg2的表达特点.结合组织芯片相关病例信息进行统计学分析.结果 32例结直肠癌组织Ndrg2表达显著低于其自身癌旁组织及正常组织,癌旁组织中的表达也显著低于正常组织中的表达.组织芯片统计分析显示,不同分化程度结直肠癌组织Ndrg2的表达差异有统计学意义(P=0.005);而Ndrg2表达与患者的年龄、性别、肿瘤部位、结直肠癌浸润深度、淋巴转移及UICC分期无关.结论 Ndrg2可能参与调控结直肠癌细胞的分化过程.